Madrigal Pharmaceuticals (MDGL) Current Assets (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Current Assets data on file, last reported at $1.2 billion in Q1 2026.

• Current Assets for Q1 2026 came in at $1.2 billion, up 19.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 19.67% YoY), and the FY2025 annual result was $1.2 billion, up 20.61% from the prior year.
• Current Assets declined to $1.2 billion in Q1 2026 per MDGL's latest filing, from $1.2 billion in the prior quarter.
• Over five years, Current Assets peaked at $1.3 billion in Q3 2025 and troughed at $157.1 million in Q3 2022.
• A 5-year average of $734.6 million and a median of $988.0 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2024: Current Assets slumped 48.14% in 2022, then soared 351.72% in 2024.
• A 5-year view of Current Assets shows it stood at $361.4 million in 2022, then surged by 76.35% to $637.3 million in 2023, then jumped by 62.08% to $1.0 billion in 2024, then grew by 20.61% to $1.2 billion in 2025, then dropped by 5.09% to $1.2 billion in 2026.
• Business Quant data shows MDGL's Current Assets at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.3 billion in Q3 2025.